Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Decrease in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 57,300 shares, a decline of 67.1% from the January 31st total of 174,100 shares. Currently, 7.7% of the shares of the stock are short sold. Based on an average trading volume of 148,900 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating and set a $350.00 target price on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in Windtree Therapeutics, Inc. (NASDAQ:WINT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned about 1.08% of Windtree Therapeutics at the end of the most recent reporting period. Institutional investors own 29.33% of the company’s stock.

Windtree Therapeutics Price Performance

Windtree Therapeutics stock opened at $3.18 on Friday. The business has a 50 day moving average of $9.80 and a 200-day moving average of $91.61. Windtree Therapeutics has a 1 year low of $3.12 and a 1 year high of $737.43. The company has a market capitalization of $2.38 million, a P/E ratio of -0.19 and a beta of 0.54.

Windtree Therapeutics (NASDAQ:WINT) last released its quarterly earnings data on Tuesday, November 26th. The company reported ($211.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($113.50) by ($98.00). Equities analysts anticipate that Windtree Therapeutics will post -5.66 EPS for the current year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.